• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline

    Gabrielle Lakusta
    Dec. 06, 2018 08:35AM PST
    Life Science Investing News

    Rexahn Pharmaceuticals (NYSE:RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced an operational restructuring that will enable a more efficient development of its clinical-stage oncology pipeline. As quoted in the press release: Rexahn is lowering its operating costs including eliminating six positions, …

    Rexahn Pharmaceuticals (NYSE:RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced an operational restructuring that will enable a more efficient development of its clinical-stage oncology pipeline.

    As quoted in the press release:

    Rexahn is lowering its operating costs including eliminating six positions, reducing the company’s workforce to 10. “In order to maximize shareholder value, we are prioritizing our resource utilization, including by reducing overhead expenses and discretionary spending,” said Douglas Swirsky, president and chief executive officer of Rexahn. “These cost reductions are expected to extend our operating runway into the fourth quarter of 2019 and provide further savings in 2020 and beyond. We have retained capabilities to continue the development of RX-3117 and RX-5902 as we explore opportunities to extract full value from these programs.”

    The company intends to primarily focus its near-term efforts on the ongoing Phase 2 clinical trial of RX-3117 in combination with ABRAXANE® (nab-paclitaxel) in patients newly diagnosed with metastatic pancreatic cancer. Encouraging preliminary safety and efficacy data from this trial was presented in October at the 5th NCI Pancreatic Cancer Symposium. Updated data from this study will be presented at the American Society of Clinical Oncology Annual Gastrointestinal Cancers Symposium (ASCO-GI) being held January 17-19, 2019 in San Francisco, CA.

    Click here to read the full press release.

    nyse:rnnrexahn pharmaceuticals
    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—